UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,010,129 shares of the biotechnology company's stock after selling 144,121 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.61% of Arrowhead Pharmaceuticals worth $37,790,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. R Squared Ltd purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $38,000. Van ECK Associates Corp raised its stake in shares of Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after buying an additional 1,250 shares during the period. KBC Group NV lifted its position in shares of Arrowhead Pharmaceuticals by 45.9% during the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after buying an additional 1,644 shares during the last quarter. Envestnet Portfolio Solutions Inc. purchased a new stake in Arrowhead Pharmaceuticals in the 4th quarter worth about $190,000. Finally, First Citizens Bank & Trust Co. bought a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $205,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR traded up $0.19 during midday trading on Wednesday, hitting $15.56. The company had a trading volume of 1,540,658 shares, compared to its average volume of 1,507,128. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41. The company has a fifty day moving average of $13.32 and a two-hundred day moving average of $17.54. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -3.01 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $2.81. The firm had revenue of $542.71 million for the quarter, compared to analysts' expectations of $116.27 million. During the same period in the prior year, the firm earned ($1.02) EPS. On average, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, CEO Christopher Richard Anzalone sold 51,425 shares of the firm's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total transaction of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares of the company's stock, valued at approximately $61,220,021.39. This trade represents a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders have sold a total of 275,880 shares of company stock valued at $4,034,037 over the last ninety days. 4.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on ARWR shares. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Citigroup cut their price target on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, B. Riley reiterated a "buy" rating and set a $38.00 price target (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $42.13.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.